Soliton, Inc. SOLY
Day range unavailable
52-week range unavailable
Discussion (139)
Sign in to join the discussion
HOUSTON, Dec. 10, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced the appointment of Mary Stoll as Senior Director of Clinical Development. Ms. Stoll will have responsibility for direct oversight of all clinical activities of the Company's Rapid Acoustic Pulse ("RAP") device for tattoo removal, improvement in the appearance of cellulite, keloid (scarring), and additional pipeline indications.
Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. (PRNewsfoto/Soliton, Inc.)
Dr. Chris Capelli, Soliton's President, CEO and co-founder, commented, "In line with our growth plans, Mary is a welcomed addition to the Soliton team and her appointment corresponds with our strategic increase in clinical activity planned for 2020. Mary brings deep knowledge and related experience, which gives me great confidence in our ability to execute our on-going clinical strategy."
Mary Stoll joins Soliton from Cytrellis Biosystems where she served as Senior Director of Clinical Operations. At Cytrellis, she oversaw and lead all clinical operations activities for new technology targeting skin laxity and was responsible for promoting, executing, and establishing clinical strategies in line with the Company's mission and vision. Prior to her tenure with Cytrellis, she was the Executive Director of Clinical Services at Cynosure, a laser Company acquired by Hologic, Inc. Ms. Stoll holds a Bachelor in Science Health and Science Studies and a nursing degree both from Quinnipiac University.
"We believe Mary's directly-related clinical dermatology experience will help Soliton accelerate and improve our research and development activities. It is evident that Mary's experience directly overlaps the role she will fill at Soliton," states Joe Tanner, the Chief Operating Officer, "but more importantly, we believe she is exactly the right fit within our culture of strong teamwork."
Join our more than 200K fans here to follow the Company: https://soly-investors.com
$22 price target !!! $SOLY
Hal. We start selling Qtr 1. 2020. Everything is going to be AOhkayy!! $SOLY
$SOLY Christmas came early !!!
$SOLY smh
$SOLY HOUSTON, Dec. 3, 2019 /PRNewswire/ -- Medical device innovation company Soliton, Inc. (Nasdaq: SOLY) today announced that it has engaged Tailfin, an Atlanta based brand and marketing firm, to help develop brand strategy and marketing and sales materials to help power the launch of Soliton's Rapid Acoustic Pulse ("RAP") device for tattoo removal. RAP is a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center. Tailfin, a firm with nearly two decades of experience in bringing medical device brands to market, will help shape positioning and messaging for the new technology launch.
Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. (PRNewsfoto/Soliton, Inc.)
"Our partnership with Tailfin is an important step in the commercialization of our innovative RAP device – a device we believe may revolutionize tattoo removal. Tailfin is an ideal partner to help us build the brand around this technology, with engaging, effective and informational brand storytelling that will clearly articulate the advantages our new technology delivers," says Dr. Chris Capelli, Soliton President, CEO and co-founder. "We are excited to reveal our pointed and powerful marketing strategy which we anticipate will drive physician and consumer awareness and fuel sustainable growth we believe will support long-term shareholder value."
Join our more than 200K fans here to follow the Company: https://soly-investors.com
With work already well underway, the Soliton and Tailfin teams look to have initial brand elements ready in Q1 2020 with planned enhancements scheduled to roll out in the months to follow.
What do you want to know Arkansas? $SOLY
$SOLY volume picking up!!